Ranbaxy Laboratories: India's First Multinational


IBS CDC IBS CDC IBS CDC IBS CDC RSS Feed
 
Case Studies | Case Study in Business, Management, Operations, Strategy, Case Study

ICMR HOME | Case Studies Collection

Case Details:

Case Code : BSTA031
Case Length : 17 Pages
Period : 2003 - 2004
Organization : Ranbaxy
Pub Date : 2004
Teaching Note :Not Available
Countries : Global
Industry : Pharmaceuticals

To download Ranbaxy Laboratories: India's First Multinational case study (Case Code: BSTA031) click on the button below, and select the case from the list of available cases:





Price:

For delivery in electronic format: Rs. 500;
For delivery through courier (within India): Rs. 500 + Rs. 25 for Shipping & Handling Charges


Business Strategy Case Studies
Case Studies Collection
Business Strategy Short Case Studies
View Detailed Pricing Info
How To Order This Case
Business Case Studies
Area Specific Case Studies
Industry Wise Case Studies
Company Wise Case Studies



Please note:

This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.

<< Previous

Introduction

Ranbaxy Laboratories (Ranbaxy), one of India's leading pharmaceutical companies recorded sales of Rs. 37.14 billion and a net profit of Rs. 6.48 billion in 2002. The company's global forays had paid rich dividends. Under the leadership of, first Parvender Singh and subsequently, D S Brar, Ranbaxy had made significant progress in its plans to become an international research based company. Ranbaxy had a strong presence in the US generics market. But in late 2003, when CEO D S Brar announced that he would resign shortly, analysts became concerned. They wondered whether a phenomenon quite visible in other Indian family controlled businesses might repeat itself at Ranbaxy – the promoters getting involved in day-to-day management at the expense of professional managers.

As Brar prepared to make way for his successor, Brian Tempest, many senior executives put in their papers. These included Rashmi Barbhaiya, R&D Chief, K Srinivas, Head of API (Active Pharma Ingredients) business, Vinod Dhawan, Regional Director, Asian-Pacific, Vijaya Sampat, VP-Legal and Company Affairs and Sanjeev Sethi, Director, Regulatory Affairs. Press reports speculated the impact of these changes on one of India's most respected companies. Despite these concerns, the business model that Ranbaxy had built was unique in many ways.

Background

Ranbaxy was founded in Amritsar in 1937 by Ranjit Singh and Dr Gurbax singh, who distributed vitamins and anti-tuberculosis drugs for a Japanese pharmaceutical company. After the Second World War, Ranbaxy continued as a distributor. In 1951, Ranbaxy took over the North Indian distribution for Lapetit, an Italian pharmaceutical company...

Excerpts >>



 

Case Studies Links:- Case Studies, Short Case Studies, Simplified Case Studies.

Other Case Studies:- Multimedia Case Study, Cases in Other Languages.

Business Reports Link:- Business Reports.

Books:- Textbooks, Work Books, Case Study Volumes.